We seek to renew funding for this successful physician-scientist training program that was first awarded in January 2007. The goal of our program is to develop two integrated but separate pathways that provide integrated scientific training in "clinical trials, epidemiology, comparative effectiveness, and outcomes research" and in "translational approaches in cellular and animal models of inflammation." In this renewal, we propose to include faculty mentors from the Department of Pediatrics and post- doctoral trainees who will focus on pediatric and neonatal lung diseases. The fundamental component of our program has been to develop a strong mentorship platform to support successful academic careers for physician-scientists;one that employs an intensive and diverse approach to formal scientific training for candidates who have completed or will complete clinical training in adult pulmonary medicine, critical care medicine, or neonatology and who have a strong commitment to an academic career.
We aim to train highly select individuals in a scientific body of knowledge that is related to the primary and secondary role of inflammation and innate immunity in a wide spectrum of lung and pulmonary vascular diseases. We believe that this scientific platform pertains broadly to the widest variety of lung diseases that share a prominent inflammatory feature and include the very prevalent diseases of asthma and COPD, interstitial lung disease, occupational and environmental lung disease, acute respiratory distress syndrome, chronic lung disease of infancy and pulmonary hypertension in the newborn. We hypothesize that an integrated program that is focused on both clinical and basic research in the context of both pediatric and adult lung diseases will inspire a new generation of successful physician-scientists. All trainees will develop an individualized research program, learn to write grant proposals, and receive career counseling and assistance in academic job placement. The progress of the trainees and their mentors will be closely monitored by a research advisory committee, internal executive committee, external advisory board, and the principal investigator. Our program is designed to emphasize novel molecular approaches in an ethical and scientifically responsible environment and has a strong commitment to attracting individuals from under-represented minorities.
Lay Description: We aim to develop a strong mentorship platform to support an intensive and diverse approach to formal scientific training for candidates who have completed or will complete clinical training in adult pulmonary medicine, critical care medicine, or neonatology and who have a strong commitment to an academic career. We hypothesize that an integrated program that is focused on both clinical and basic research in the context of both pediatric and adult lung diseases will inspire a new generation of successful physician-scientists. Our program is designed to emphasize novel molecular approaches in an ethical and scientifically responsible environment and has a strong commitment to attracting individuals from under-represented minorities.
|Mirsaeidi, Mehdi; Machado, Roberto F; Schraufnagel, Dean et al. (2015) Racial difference in sarcoidosis mortality in the United States. Chest 147:438-49|
|Velayati, Ali Akbar; Farnia, Parissa; Mozafari, Mohadese et al. (2015) Identification and genotyping of Mycobacterium tuberculosis isolated from water and soil samples of a metropolitan city. Chest 147:1094-102|
|Au, Sonoa; Mirsaeidi, Mehdi; Aronson, Iris K et al. (2014) Adalimumab Induced Subcutaneous Nodular Sarcoidosis; A Rare Side Effect of Tumor Necrosis Factor-? Inhibitor. Sarcoidosis Vasc Diffuse Lung Dis 31:249-51|
|Belvitch, Patrick; Adyshev, Djanybek; Elangovan, Venkateswaran R et al. (2014) Proline-rich region of non-muscle myosin light chain kinase modulates kinase activity and endothelial cytoskeletal dynamics. Microvasc Res 95:94-102|
|Prieto-Centurion, Valentin; Rolle, Andrew J; Au, David H et al. (2014) Multicenter study comparing case definitions used to identify patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 190:989-95|
|Mirsaeidi, Mehdi; Schraufnagel, Dean E (2014) Pneumococcal vaccines: understanding centers for disease control and prevention recommendations. Ann Am Thorac Soc 11:980-5|
|Sweiss, Nadera J; Lower, Elyse E; Mirsaeidi, Mehdi et al. (2014) Rituximab in the treatment of refractory pulmonary sarcoidosis. Eur Respir J 43:1525-8|
|Krishnan, Jerry A; Prieto-Centurion, Valentin (2014) Reducing the risk of rehospitalization in patients with chronic obstructive pulmonary disease exacerbations. Fewer known unknowns. Ann Am Thorac Soc 11:797-8|
|Mirsaeidi, Mehdi; Ebrahimi, Golnaz; Allen, Mary Beth et al. (2014) Pneumococcal vaccine and patients with pulmonary diseases. Am J Med 127:886.e1-8|
|Sweiss, Nadera J; Noth, Imre; Mirsaeidi, Mehdi et al. (2014) Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 31:46-54|
Showing the most recent 10 out of 21 publications